{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:43:48Z","timestamp":1790210628885,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In chronic kidney disease, ferric citrate has been shown to be an effective phosphate binder and source of enteral iron; however, the effects of ferric citrate on the kidney have been less well-studied. Here, in <jats:italic>Col4\u03b13<\/jats:italic> knockout mice\u2014a murine model of progressive chronic kidney disease, we evaluated the effects of five weeks of 1% ferric citrate dietary supplementation. As expected, ferric citrate lowered serum phosphate concentrations and increased serum iron levels in the <jats:italic>Col4\u03b13<\/jats:italic> knockout mice. Consistent with decreased enteral phosphate absorption and possibly improved iron status, ferric citrate greatly reduced circulating fibroblast growth factor 23 levels. Interestingly, ferric citrate also lessened systemic inflammation, improved kidney function, reduced albuminuria, and decreased kidney inflammation and fibrosis, suggesting renoprotective effects of ferric citrate in the setting of chronic kidney disease. The factors mediating possible ferric citrate renoprotection, the mechanisms by which they may act, and whether ferric citrate affects chronic kidney disease progression in humans deserves further study.<\/jats:p>","DOI":"10.1038\/s41598-022-10842-4","type":"journal-article","created":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T12:03:03Z","timestamp":1650715383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Renoprotective effects of ferric citrate in a mouse model of chronic kidney disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Mark R.","family":"Hanudel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Czaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gabayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Ganz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,23]]},"reference":[{"issue":"9","key":"10842_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40265-019-01125-w","volume":"79","author":"T Ganz","year":"2019","unstructured":"Ganz, T., Bino, A. & Salusky, I. B. Mechanism of action and clinical attributes of Auryxia((R)) (Ferric Citrate). Drugs 79(9), 957\u2013968 (2019).","journal-title":"Drugs"},{"issue":"5","key":"10842_CR2","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2014.10.014","volume":"65","author":"GA Block","year":"2015","unstructured":"Block, G. A. et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3\u20135. Am. J. Kidney Dis. 65(5), 728\u2013736 (2015).","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"10842_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2215\/CJN.05170513","volume":"9","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama, K. et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin. J. Am. Soc. Nephrol. 9(3), 543\u2013552 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"6","key":"10842_CR4","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1681\/ASN.2016101053","volume":"28","author":"S Fishbane","year":"2017","unstructured":"Fishbane, S. et al. Effects of Ferric citrate in patients with nondialysis-dependent CKD and Iron deficiency Anemia. J. Am. Soc. Nephrol. 28(6), 1851\u20131858 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10842_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1681\/ASN.2014020212","volume":"26","author":"JB Lewis","year":"2015","unstructured":"Lewis, J. B. et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J. Am. Soc. Nephrol. 26(2), 493\u2013503 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10842_CR6","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/ndt\/gft483","volume":"29","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama, K. et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol. Dial Transplant. 29(5), 1053\u20131060 (2014).","journal-title":"Nephrol. Dial Transplant."},{"issue":"4","key":"10842_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1172\/JCI200419081","volume":"113","author":"T Shimada","year":"2004","unstructured":"Shimada, T. et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113(4), 561\u2013568 (2004).","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10842_CR8","doi-asserted-by":"publisher","first-page":"F282","DOI":"10.1152\/ajprenal.90742.2008","volume":"297","author":"J Gattineni","year":"2009","unstructured":"Gattineni, J. et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am. J. Physiol. Renal. Physiol. 297(2), F282-291 (2009).","journal-title":"Am. J. Physiol. Renal. Physiol."},{"issue":"11","key":"10842_CR9","doi-asserted-by":"publisher","first-page":"9843","DOI":"10.1074\/jbc.M210490200","volume":"278","author":"XY Bai","year":"2003","unstructured":"Bai, X. Y. et al. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J. Biol. Chem. 278(11), 9843\u20139849 (2003).","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10842_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada, T. et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19(3), 429\u2013435 (2004).","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10842_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1152\/physrev.00014.2015","volume":"96","author":"S Christakos","year":"2016","unstructured":"Christakos, S. et al. Vitamin D: Metabolism, molecular mechanism of action, and pleiotropic effects. Physiol. Rev. 96(1), 365\u2013408 (2016).","journal-title":"Physiol. Rev."},{"issue":"12","key":"10842_CR12","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova, T. et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79(12), 1370\u20131378 (2011).","journal-title":"Kidney Int."},{"issue":"6","key":"10842_CR13","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","volume":"64","author":"T Larsson","year":"2003","unstructured":"Larsson, T. et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 64(6), 2272\u20132279 (2003).","journal-title":"Kidney Int."},{"issue":"7","key":"10842_CR14","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1681\/ASN.2005010052","volume":"16","author":"O Gutierrez","year":"2005","unstructured":"Gutierrez, O. et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 16(7), 2205\u20132215 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10842_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2215\/CJN.05840513","volume":"9","author":"AA Portale","year":"2014","unstructured":"Portale, A. A. et al. Disordered FGF23 and mineral metabolism in children with CKD. Clin. J. Am. Soc. Nephrol. 9(2), 344\u2013353 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"10842_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1053\/j.ajkd.2019.07.022","volume":"75","author":"T Isakova","year":"2020","unstructured":"Isakova, T. et al. Longitudinal evolution of markers of mineral metabolism in patients with CKD: the chronic renal insufficiency cohort (CRIC) study. Am. J. Kidney Dis. 75(2), 235\u2013244 (2020).","journal-title":"Am. J. Kidney Dis."},{"issue":"23","key":"10842_CR17","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova, T. et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305(23), 2432\u20132439 (2011).","journal-title":"JAMA"},{"issue":"9","key":"10842_CR18","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1681\/ASN.2006080936","volume":"18","author":"D Fliser","year":"2007","unstructured":"Fliser, D. et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 18(9), 2600\u20132608 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"11","key":"10842_CR19","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.2215\/CJN.02110216","volume":"11","author":"AA Portale","year":"2016","unstructured":"Portale, A. A. et al. Fibroblast growth factor 23 and risk of CKD progression in children. Clin. J. Am. Soc. Nephrol. 11(11), 1989\u20131998 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"8","key":"10842_CR20","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1210\/jc.2006-0021","volume":"91","author":"DM Antoniucci","year":"2006","unstructured":"Antoniucci, D. M., Yamashita, T. & Portale, A. A. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J. Clin. Endocrinol. Metab. 91(8), 3144\u20133149 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10842_CR21","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1359\/jbmr.060507","volume":"21","author":"SM Burnett","year":"2006","unstructured":"Burnett, S. M. et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J. Bone Miner. Res. 21(8), 1187\u20131196 (2006).","journal-title":"J. Bone Miner. Res."},{"issue":"46","key":"10842_CR22","doi-asserted-by":"publisher","first-page":"E1146","DOI":"10.1073\/pnas.1110905108","volume":"108","author":"EG Farrow","year":"2011","unstructured":"Farrow, E. G. et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc. Natl. Acad. Sci. U S A 108(46), E1146-1155 (2011).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"2","key":"10842_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/jbmr.2049","volume":"29","author":"EL Clinkenbeard","year":"2014","unstructured":"Clinkenbeard, E. L. et al. Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J. Bone Miner. Res. 29(2), 361\u2013369 (2014).","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10842_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/ki.2015.290","volume":"89","author":"V David","year":"2016","unstructured":"David, V. et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 89(1), 135\u2013146 (2016).","journal-title":"Kidney Int."},{"issue":"6","key":"10842_CR25","doi-asserted-by":"publisher","first-page":"F1369","DOI":"10.1152\/ajprenal.00281.2016","volume":"311","author":"MR Hanudel","year":"2016","unstructured":"Hanudel, M. R. et al. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. Am. J. Physiol. Renal. Physiol. 311(6), F1369\u2013F1377 (2016).","journal-title":"Am. J. Physiol. Renal. Physiol."},{"issue":"8","key":"10842_CR26","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1681\/ASN.2018101016","volume":"30","author":"GA Block","year":"2019","unstructured":"Block, G. A. et al. A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD. J. Am. Soc. Nephrol. 30(8), 1495\u20131504 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10842_CR27","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.kint.2019.07.026","volume":"96","author":"C Francis","year":"2019","unstructured":"Francis, C. et al. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease. Kidney Int. 96(6), 1346\u20131358 (2019).","journal-title":"Kidney Int."},{"issue":"1","key":"10842_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1124\/jpet.118.249961","volume":"367","author":"W Jing","year":"2018","unstructured":"Jing, W. et al. Phosphate binder, ferric citrate, attenuates anemia, renal dysfunction, oxidative stress, inflammation, and fibrosis in 5\/6 nephrectomized CKD rats. J. Pharmacol. Exp. Ther. 367(1), 129\u2013137 (2018).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10842_CR29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1755-1536-7-4","volume":"7","author":"F Genovese","year":"2014","unstructured":"Genovese, F. et al. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?. Fibrogenesis Tissue Repair 7(1), 4 (2014).","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"5","key":"10842_CR30","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/ki.1989.281","volume":"36","author":"K Lau","year":"1989","unstructured":"Lau, K. Phosphate excess and progressive renal failure: the precipitation-calcification hypothesis. Kidney Int. 36(5), 918\u2013937 (1989).","journal-title":"Kidney Int."},{"issue":"6","key":"10842_CR31","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/ki.2013.213","volume":"84","author":"JL Finch","year":"2013","unstructured":"Finch, J. L. et al. Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification. Kidney Int. 84(6), 1145\u20131153 (2013).","journal-title":"Kidney Int."},{"issue":"4","key":"10842_CR32","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/ki.2013.194","volume":"84","author":"S Zhang","year":"2013","unstructured":"Zhang, S. et al. Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease. Kidney Int. 84(4), 713\u2013721 (2013).","journal-title":"Kidney Int."},{"issue":"1","key":"10842_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrneph.2016.164","volume":"13","author":"MG Vervloet","year":"2017","unstructured":"Vervloet, M. G. et al. The role of phosphate in kidney disease. Nat. Rev. Nephrol. 13(1), 27\u201338 (2017).","journal-title":"Nat. Rev. Nephrol."},{"issue":"2","key":"10842_CR34","doi-asserted-by":"publisher","first-page":"e0150093","DOI":"10.1371\/journal.pone.0150093","volume":"11","author":"ZJ Shen","year":"2016","unstructured":"Shen, Z. J. et al. Phosphate-induced renal fibrosis requires the Prolyl Isomerase Pin1. PLoS ONE 11(2), e0150093 (2016).","journal-title":"PLoS ONE"},{"key":"10842_CR35","doi-asserted-by":"crossref","unstructured":"Clinkenbeard, E. L. et al. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD. JCI Insight 4(4), e123817 (2019).","DOI":"10.1172\/jci.insight.123817"},{"key":"10842_CR36","doi-asserted-by":"crossref","unstructured":"Shiizaki, K. et al. Calcium phosphate microcrystals in the renal tubular fluid accelerate chronic kidney disease progression. J. Clin. Invest. 131(16), e145693 (2021).","DOI":"10.1172\/JCI145693"},{"issue":"1","key":"10842_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000339054","volume":"30","author":"Z Chen","year":"2012","unstructured":"Chen, Z. et al. Inorganic phosphate stimulates fibronectin expression in renal fibroblasts. Cell Physiol. Biochem. 30(1), 151\u2013159 (2012).","journal-title":"Cell Physiol. Biochem."},{"key":"10842_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-nutr-071816-064607","volume":"37","author":"AR Chang","year":"2017","unstructured":"Chang, A. R. & Anderson, C. Dietary Phosphorus Intake and the Kidney. Annu. Rev. Nutr. 37, 321\u2013346 (2017).","journal-title":"Annu. Rev. Nutr."},{"issue":"12","key":"10842_CR39","doi-asserted-by":"publisher","first-page":"F1418","DOI":"10.1152\/ajprenal.00633.2013","volume":"306","author":"S Yamada","year":"2014","unstructured":"Yamada, S. et al. Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia. Am. J. Physiol. Renal. Physiol. 306(12), F1418-1428 (2014).","journal-title":"Am. J. Physiol. Renal. Physiol."},{"issue":"2","key":"10842_CR40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3164\/jcbn.16-117","volume":"61","author":"K Sugihara","year":"2017","unstructured":"Sugihara, K. et al. Dietary phosphate exacerbates intestinal inflammation in experimental colitis. J. Clin. Biochem. Nutr. 61(2), 91\u201399 (2017).","journal-title":"J. Clin. Biochem. Nutr."},{"issue":"11","key":"10842_CR41","first-page":"2077","volume":"76","author":"J Voelkl","year":"2019","unstructured":"Voelkl, J. et al. Signaling pathways involved in vascular smooth muscle cell calcification during hyperphosphatemia. Cell Mol. Life Sci. 76(11), 2077\u20132091 (2019).","journal-title":"Cell Mol. Life Sci."},{"key":"10842_CR42","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu, T. et al. NF-kappaB signaling in inflammation. Signal Transduct. Target Ther. 2, 17023 (2017).","journal-title":"Signal Transduct. Target Ther."},{"key":"10842_CR43","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/978-981-13-8871-2_18","volume":"1165","author":"XM Meng","year":"2019","unstructured":"Meng, X. M. Inflammatory mediators and renal fibrosis. Adv. Exp. Med. Biol. 1165, 381\u2013406 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"issue":"9","key":"10842_CR44","doi-asserted-by":"publisher","first-page":"e44161","DOI":"10.1371\/journal.pone.0044161","volume":"7","author":"B Dai","year":"2012","unstructured":"Dai, B. et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS ONE 7(9), e44161 (2012).","journal-title":"PLoS ONE"},{"issue":"1","key":"10842_CR45","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1038\/s41598-017-02709-w","volume":"7","author":"ER Smith","year":"2017","unstructured":"Smith, E. R. et al. FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts. Sci. Rep. 7(1), 3345 (2017).","journal-title":"Sci. Rep."},{"issue":"2","key":"10842_CR46","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.18632\/aging.202448","volume":"13","author":"H Hao","year":"2021","unstructured":"Hao, H. et al. Excessive fibroblast growth factor 23 promotes renal fibrosis in mice with type 2 cardiorenal syndrome. Aging (Albany NY) 13(2), 2982\u20133009 (2021).","journal-title":"Aging (Albany NY)"},{"issue":"5","key":"10842_CR47","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","volume":"90","author":"S Singh","year":"2016","unstructured":"Singh, S. et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 90(5), 985\u2013996 (2016).","journal-title":"Kidney Int."},{"issue":"11","key":"10842_CR48","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.3324\/haematol.2017.167882","volume":"102","author":"EL Clinkenbeard","year":"2017","unstructured":"Clinkenbeard, E. L. et al. Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica 102(11), e427\u2013e430 (2017).","journal-title":"Haematologica"},{"issue":"1","key":"10842_CR49","doi-asserted-by":"publisher","first-page":"F132","DOI":"10.1152\/ajprenal.00081.2017","volume":"314","author":"S Rabadi","year":"2018","unstructured":"Rabadi, S. et al. Acute blood loss stimulates fibroblast growth factor 23 production. Am. J. Physiol. Renal. Physiol. 314(1), F132\u2013F139 (2018).","journal-title":"Am. J. Physiol. Renal. Physiol."},{"issue":"12","key":"10842_CR50","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1093\/ndt\/gfy189","volume":"34","author":"MR Hanudel","year":"2019","unstructured":"Hanudel, M. R. et al. Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrol. Dial Transplant. 34(12), 2057\u20132065 (2019).","journal-title":"Nephrol. Dial Transplant."},{"issue":"6","key":"10842_CR51","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/ki.2013.526","volume":"85","author":"D Spichtig","year":"2014","unstructured":"Spichtig, D. et al. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Kidney Int. 85(6), 1340\u20131350 (2014).","journal-title":"Kidney Int."},{"issue":"1","key":"10842_CR52","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.kint.2017.01.015","volume":"92","author":"ML Mace","year":"2017","unstructured":"Mace, M. L. et al. Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia. Kidney Int. 92(1), 165\u2013178 (2017).","journal-title":"Kidney Int."},{"issue":"3","key":"10842_CR53","doi-asserted-by":"publisher","first-page":"e0191706","DOI":"10.1371\/journal.pone.0191706","volume":"13","author":"H Sugiura","year":"2018","unstructured":"Sugiura, H. et al. Fibroblast growth factor 23 is upregulated in the kidney in a chronic kidney disease rat model. PLoS ONE 13(3), e0191706 (2018).","journal-title":"PLoS ONE"},{"issue":"2","key":"10842_CR54","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3324\/haematol.2019.237040","volume":"106","author":"R Agoro","year":"2021","unstructured":"Agoro, R. et al. C-FGF23 peptide alleviates hypoferremia during acute inflammation. Haematologica 106(2), 391\u2013403 (2021).","journal-title":"Haematologica"},{"key":"10842_CR55","doi-asserted-by":"crossref","unstructured":"Radhakrishnan, K. et al. Orphan nuclear receptor ERR-gamma regulates hepatic FGF23 production in acute kidney injury. Proc. Natl. Acad. Sci. U S A 118(16), e2022841118 (2021).","DOI":"10.1073\/pnas.2022841118"},{"issue":"5\u20136","key":"10842_CR56","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/08977194.2016.1273222","volume":"34","author":"Y Nakashima","year":"2016","unstructured":"Nakashima, Y. et al. Expression and localization of fibroblast growth factor (FGF)23 and Klotho in the spleen: its physiological and functional implications. Growth Factors 34(5\u20136), 196\u2013202 (2016).","journal-title":"Growth Factors"},{"issue":"6","key":"10842_CR57","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/ndt\/gfw376","volume":"32","author":"S Bansal","year":"2017","unstructured":"Bansal, S. et al. Spleen contributes significantly to increased circulating levels of fibroblast growth factor 23 in response to lipopolysaccharide-induced inflammation. Nephrol. Dial Transplant. 32(6), 960\u2013968 (2017).","journal-title":"Nephrol. Dial Transplant."},{"key":"10842_CR58","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3389\/fphys.2018.01494","volume":"9","author":"D Egli-Spichtig","year":"2018","unstructured":"Egli-Spichtig, D., Zhang, M. Y. H. & Perwad, F. Fibroblast growth factor 23 Expression is increased in multiple organs in mice with folic acid-induced acute kidney injury. Front. Physiol. 9, 1494 (2018).","journal-title":"Front. Physiol."},{"issue":"9","key":"10842_CR59","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1210\/jc.2012-1811","volume":"97","author":"ER Smith","year":"2012","unstructured":"Smith, E. R. et al. Biological variability of plasma intact and C-terminal FGF23 measurements. J. Clin. Endocrinol. Metab. 97(9), 3357\u20133365 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10842_CR60","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1210\/jc.2009-1603","volume":"95","author":"T Shimada","year":"2010","unstructured":"Shimada, T. et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J. Clin. Endocrinol. Metab. 95(2), 578\u2013585 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10842_CR61","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/01.mnh.0000447020.74593.6f","volume":"23","author":"M Wolf","year":"2014","unstructured":"Wolf, M. & White, K. E. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr. Opin. Nephrol. Hypertens. 23(4), 411\u2013419 (2014).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"6","key":"10842_CR62","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1182\/blood-2007-04-087593","volume":"110","author":"L Lin","year":"2007","unstructured":"Lin, L. et al. Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2\/4. Blood 110(6), 2182\u20132189 (2007).","journal-title":"Blood"},{"issue":"7","key":"10842_CR63","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1182\/blood-2002-10-3235","volume":"101","author":"E Nemeth","year":"2003","unstructured":"Nemeth, E. et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101(7), 2461\u20132463 (2003).","journal-title":"Blood"},{"issue":"11","key":"10842_CR64","doi-asserted-by":"publisher","first-page":"7806","DOI":"10.1074\/jbc.M008922200","volume":"276","author":"CH Park","year":"2001","unstructured":"Park, C. H. et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 276(11), 7806\u20137810 (2001).","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10842_CR65","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI200420945","volume":"113","author":"E Nemeth","year":"2004","unstructured":"Nemeth, E. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113(9), 1271\u20131276 (2004).","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10842_CR66","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/sj.ki.5000105","volume":"69","author":"CP Kovesdy","year":"2006","unstructured":"Kovesdy, C. P. et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 69(3), 560\u2013564 (2006).","journal-title":"Kidney Int."},{"issue":"2","key":"10842_CR67","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1440-1797.2008.01065.x","volume":"14","author":"ML Thorp","year":"2009","unstructured":"Thorp, M. L. et al. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology (Carlton) 14(2), 240\u2013246 (2009).","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"10842_CR68","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ndt\/gfz192","volume":"36","author":"AA Awan","year":"2021","unstructured":"Awan, A. A. et al. Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. Nephrol. Dial Transplant. 36(1), 129\u2013136 (2021).","journal-title":"Nephrol. Dial Transplant."},{"key":"10842_CR69","unstructured":"Yadav, A. K. et al. Serum catalytic iron and progression of chronic kidney disease: findings from the ICKD study. Nephrol. Dial Transplant. gfab271. (2021)"},{"key":"10842_CR70","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00467-021-05191-9","volume":"37","author":"E Patino","year":"2021","unstructured":"Patino, E. & Akchurin, O. Erythropoiesis-independent effects of iron in chronic kidney disease. Pediatr. Nephrol. 37(4), 777\u2013788 (2022).","journal-title":"Pediatr. Nephrol."},{"issue":"5","key":"10842_CR71","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.kint.2020.05.043","volume":"98","author":"E Patino","year":"2020","unstructured":"Patino, E. et al. Carbonyl iron and iron dextran therapies cause adverse effects on bone health in juveniles with chronic kidney disease. Kidney Int. 98(5), 1210\u20131224 (2020).","journal-title":"Kidney Int."},{"issue":"6","key":"10842_CR72","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1023\/A:1020884312053","volume":"32","author":"AA Bachmanov","year":"2002","unstructured":"Bachmanov, A. A. et al. Food intake, water intake, and drinking spout side preference of 28 mouse strains. Behav. Genet. 32(6), 435\u2013443 (2002).","journal-title":"Behav. Genet."},{"issue":"8","key":"10842_CR73","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1182\/blood-2013-08-521419","volume":"123","author":"A Kim","year":"2014","unstructured":"Kim, A. et al. A mouse model of anemia of inflammation: complex pathogenesis with partial dependence on hepcidin. Blood 123(8), 1129\u20131136 (2014).","journal-title":"Blood"},{"issue":"17","key":"10842_CR74","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood-2015-07-658419","volume":"126","author":"L Kautz","year":"2015","unstructured":"Kautz, L. et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of beta-thalassemia. Blood 126(17), 2031\u20132037 (2015).","journal-title":"Blood"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10842-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10842-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10842-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T01:54:26Z","timestamp":1669341266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10842-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,23]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10842"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10842-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,23]]},"assertion":[{"value":"21 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6695"}}